Project description
Microalgae powerhouses do it better when it comes to production of anticancer therapeutics
Demand for recombinant pharmaceutical proteins is growing globally and the use of microorganisms as small bioreactors for rapid and cost-effective production is an important area of research. Microalgae, like mammalian cell lines, enable post-transcriptional and post-translational modifications, high production quality and high protein yield. However, unlike mammalian cell culture, they offer fast large-scale production, low overall cost, low risk of contamination, and easy reproduction and distribution. MABIOS has developed a microalgae platform for producing anticancer biopharmaceuticals that could lower the cost of treatment for millions of patients worldwide. EU-funding is providing the opportunity to develop the best business plan, meet regulatory requirements, and bring the platform to market.
Fields of science
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1
Coordinator
2333 CW Leiden
Netherlands
See on map